John Libbey Eurotext

A case of repetitive seizures following immune checkpoint inhibitor therapy as a feature of autoimmune encephalitis Volume 23, numéro 5, October 2021

  • [1] Darvin P., Toor S.M., Sasidharan Nair V., Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:165. 12
  • [2] Kyi C., Postow M.A. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588:368-376. 2
  • [3] O’Byrne K. Stimulating immune responses to fight cancer: basic biology and mechanisms. Asia Pac J Clin Oncol. 2015;11:9-15. Suppl 1
  • [4] Dubey D., David W.S., Reynolds K.L., Chute D.F., Clement N.F., Cohen J.V. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol. 2020;87:659-669. 5
  • [5] Sechi E., Markovic S.N., McKeon A., Dubey D., Liewluck T., Lennon V.A. Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology. 2020;95:e2442-e2452. 17
  • [6] Vogrig A., Muñiz-Castrillo S., Joubert B., Picard G., Rogemond V., Marchal C. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020;91:772-778. 7
  • [7] Quek A.M., Britton J.W., McKeon A., So E., Lennon V.A., Shin C. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69:582-593. 5
  • [8] Toledano M., Britton J.W., McKeon A., Shin C., Lennon V.A., Quek A.M. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82:1578-1586. 18
  • [9] Salam S., Lavin T., Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;23:2016.
  • [10] Khoja L., Maurice C., Chappell M., MacMillan L., Al-Habeeb A.S., Al-Faraidy N. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res. 2016;4:175-178. 3
  • [11] Feng S., Coward J., McCaffrey E., Coucher J., Kalokerinos P., O’Byrne K. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol. 2017;12:1626-1635. 11
  • [12] Shah N., Jacob J., Househ Z., Shiner E., Baird L., Soudy H. Unchecked immunity: a unique case of sequential immune-related adverse events with pembrolizumab. J Immunother Cancer. 2019;7:247. 1
  • [13] Michot J.M., Bigenwald C., Champiat S., Collins M., Carbonnel F., Postel-Vinay S. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148.
  • [14] Longoria T.C., Tewari K.S. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12:1247-1253. 10
  • [15] Di Gennaro G., Quarato P.P., Onorati P., Colazza G.B., Mari F., Grammaldo J.G. Localizing significance of temporal intermittent rhythmic delta activity (TIRDA) in drug-resistant focal epilepsy. Clin Neurophysiol. 2003;114:70-78. 1
  • [16] Dubey D., Singh J., Britton J.W., Pittock S.J., Flanagan E.P., Lennon V.A. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia. 2017;58:1181-1189. 7
  • [17] Diamond B., Huerta P.T., Mina-Osorio P., Kowal C., Volpe B.T. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol. 2009;9:449-456. 6
  • [18] Brahmer J.R., Lacchetti C., Schneider B.J., Atkins M.B., Brassil K.J., Caterino J.M. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768. 17